Navigation Links
Neurocrine Biosciences Reports Third Quarter 2009 Results
Date:10/28/2009

ollaborators for development, commercial manufacturing and marketing and sales activities. In addition, the Company faces risks and uncertainties with respect to the Company's R & D pipeline including risk that the Company's urocortin 2, and VMAT2 clinical candidates will not proceed to later stage clinical trials, and risk that the Company's research programs will not identify pre-clinical candidates for further development. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2008 and Form 10-Q for the quarter ended June 30, 2009. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.

                          NEUROCRINE BIOSCIENCES, INC.
               CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                  (in thousands, except loss per share data)


                                        Three Months Ended   Nine Months Ended
                                           September 30,       September 30,
                                           -------------       -------------
                                           2009      2008      2009      2008
                                           ----      ----      ----      ----
                                            (unaudited)          (unaudited
'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
2. Neurocrine Biosciences Presents Elagolix Data
3. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
4. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
5. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
6. Neurocrine Biosciences Reports First Quarter 2008 Results
7. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
8. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
9. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
10. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
11. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014  Novation, a VHA and UHC ... breakthrough interactive features that automate key health care ... Children,s Hospital Association.  The new ... umbrella – Value Analysis, Item Master and Formulary ... address the most critical challenges brought on by ...
(Date:7/29/2014)... July 29, 2014  The BioFusionary Corporation, Inc. ... a proprietary electromagnetic induction platform with aesthetic and ... agreement under which TBC will merge with ... in an all-stock transaction. Upon completion ... on the Australian Stock Exchange under the code ...
(Date:7/29/2014)... -- Encision Inc. (OTCQB:ECIA), a medical device company owning patented ... minimally invasive surgery, today announced financial results for its ... The Company posted quarterly net revenue of $2.476 ... or $(0.02) per share. These results compare to net ... $311 thousand, or $(0.04) per share, in the year-ago ...
Breaking Medicine Technology:Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 2Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 3Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 4Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 5The BioFusionary Corporation, Inc. Announces Intent To Complete Reverse Takeover Of Australia-Based Continuation Investments Limited 2The BioFusionary Corporation, Inc. Announces Intent To Complete Reverse Takeover Of Australia-Based Continuation Investments Limited 3Encision Reports First Quarter Fiscal Year 2015 Results 2Encision Reports First Quarter Fiscal Year 2015 Results 3Encision Reports First Quarter Fiscal Year 2015 Results 4
... , , , SAN FRANCISCO, Dec. 14 ... its promised announcement about health hazards of bisphenol A (BPA), ... harm and other illnesses, in time for Christmas. , ... Natural Resources Defense Council : "Just as you rely on ...
... ,Dec. 14 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. ... received a complete response letter from the U.S. Food ... Application ("NDA") for Onrigin(TM) (laromustine) injection submitted in February ... approve the Company,s NDA in its present form and ...
Cached Medicine Technology:Toxic Chemical bisphenol A Still Not Banned By FDA; Schumer, Gillibrand Call for Ban; Govt Official Warns Public 2Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 2Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 3
(Date:7/29/2014)... Researchers who discovered a group of new materials ... prestigious research award worth a combined 2m to ... polymers could lead to a significant reduction in ... improve the health care of hospital patients across ... Surfaces in the School of Pharmacy and Paul ...
(Date:7/29/2014)... LA JOLLA, Calif. (PRWEB) July 29, 2014 ... provides a comprehensive overview of the hepatitis C (hep ... and the potential of these treatments to reduce human ... broader understanding of the impact of hep C, while ... to a new era of treatment. CHI is a ...
(Date:7/29/2014)... Lake City, UT (PRWEB) July 29, 2014 ... how Activz produce powders can help parents add nutrition ... Magazine article “Little Bites – Key market drivers in ... Whole-Food Nutrition, is pleased to announce the interview ... benefits of adding the Activz organic vegetable and fruit ...
(Date:7/29/2014)... Cold Spring Harbor, NY -- Researchers at Cold Spring Harbor ... most important tumor-suppressing protein. Called p53, this protein has been ... the fore when healthy cells sense damage to their DNA ... intense exposure to the sun,s UV rays. If the ... preprogrammed cell-death, or apoptosis. Mutant versions of p53 that ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 July 29, 2014 ... home care, is proud to announce that it is a ... inspiring online video segments; Silverado Through a Child's Eye ... , In Silverado Through a Child's Eye , ... her mom at Silverado Beverly Place, a memory care community ...
Breaking Medicine News(10 mins):Health News:Bacteria resistant materials -- £2m to get the 'inside' story 2Health News:Bacteria resistant materials -- £2m to get the 'inside' story 3Health News:CHI Releases Report Highlighting Public Impact of Hepatitis C, Opportunities for Action in US 2Health News:CHI Releases Report Highlighting Public Impact of Hepatitis C, Opportunities for Action in US 3Health News:CHI Releases Report Highlighting Public Impact of Hepatitis C, Opportunities for Action in US 4Health News:Activz Organic Fruit and Vegetable Produce Powders and Founder Frank Davis Mentioned in WholeFoods Magazine Article 2Health News:Activz Organic Fruit and Vegetable Produce Powders and Founder Frank Davis Mentioned in WholeFoods Magazine Article 3Health News:Research may explain how foremost anticancer 'guardian' protein learned to switch sides 2Health News:Silverado Selected a Winner in the 35th Annual Telly Awards for Producing Inspiring Online Video Content 2
... A major study published in the November,2007 edition of ... women who completed a study using the Brava System ... full breast size. This key,finding was based on a ... Schlenz, M.D. and Alexandra Kaider, M. Sc. The study ...
... NEW YORK, Oct. 29 The Consumer-Purchaser,Disclosure Project ... employer,organizations working to ensure that all Americans have ... applauds today,s agreement,between the Attorney General of New ... physician performance. This important agreement will,allow physician performance ...
... reminder program, TORONTO, Oct. 29 /PRNewswire/ - Organon ... free telephone-based reminder program designed to,help women remember their ... million women (Stat. Can., 2001) take oral,contraceptives everyday and ... take it at least once. Although the pill is ...
... Key Element To An Effective, Hygiene Protocol. ... WASHINGTON, Oct. 29 The recent outbreak ... as an important,reminder of the importance of routine, ... large number of people constantly live,work or play. ...
... heart despite symptom relief, experts say , , MONDAY, Oct. ... than they did 40 years ago, but not if they ... Mayo Clinic. , "When you look at persons with rheumatoid ... over the last several decades of improved survival the rest ...
... chronic tendinosis of the Achilles tendon can experience a ... of a dextrose solution, according to a recent study ... BC. , Chronic tendinosis is a common overuse injury ... affect many tendons throughout the body, said Norman J. ...
Cached Medicine News:Health News:Newly Published Study in Leading Medical Journal Further Confirms the Brava System's Non-Surgical Breast Enhancement Effectiveness 2Health News:Consumers, Health Care Purchasers Applaud Agreement On Physician Performance Reporting 2Health News:Consumers, Health Care Purchasers Applaud Agreement On Physician Performance Reporting 3Health News:Consumers, Health Care Purchasers Applaud Agreement On Physician Performance Reporting 4Health News:Canada leads the way in contraceptive compliance 2Health News:Canada leads the way in contraceptive compliance 3Health News:Spate of Staph Infections Highlight the Need for Thorough, Consistent Cleaning Regimen at Home, at School and at Work 2Health News:Rheumatoid Arthritis Death Rate Unchanged 2Health News:Rheumatoid Arthritis Death Rate Unchanged 3Health News:Ultrasound-guided injections help ease chronic Achilles tendon pain 2
... ACMI™ USA Elite System Rotating Continuous Flow ... the urologist to rotate the working element ... of the sheaths. The result no ... tangled tubing due to rotating flow ports, ...
... PC-based ECG device that can be ... an innovative software. The system enables ... using a standard 12-lead setup that ... software includes two applications: Rest ECG ...
Used for traversing and exploring urethral strictures. The malleable tip can be shaped to desired configuration. The proximal end is threaded to attach to standard followers. Supplied sterile in peel...
The removable inflation adapter allows the ureteroscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: